Our results from treating Tg-AD rats with timapiprant reveal that manipulating PGD2 signaling with DP2 antagonists could potentially mitigate plaque load, neuronal loss and microgliosis, in addition to improving cognitive outcomes in AD patients (Fig 11). This evidence concerns the gene PTGDR2 and Alzheimer disease.